Emotional distress, guilt and impact on reproductive decision-making in women with BRCA1/2 mutations Authors: Anita Caruso, Luigi Grassi, Anna Costantini, Eugenia Trotti, Rosangela Caruso, Chiara Maria Navarra, Marco Luigi Bellani, Ileana Carnevali, Elena Barbieri, Marco Cruciata, Marco Canfora, Francesca Sperati, Antonella Savarese, Elisabetta Razzaboni, Lara Guariglia Published: 2026 ABSTRACT Highlights•Guilt may shape reproductive choices in BRCA1/2 carriers.•Omnipotent responsibility guilt exceeds normative values.•Transmission risk evokes stronger distress than test disclosure.•Survivor guilt links genetic status to motherhood decisions.•Depression rates are higher than in the general population. Introduction Breast cancer is the most frequently diagnosed carcinoma among women worldwide and remains one of the leading causes of cancer-related mortality in females [1]. Approximately 5–10% of all breast cancers are associated with hereditary genetic mutations, among which BRCA1 and BRCA2 are the most investigated genes. Pathogenic variants in these genes confer a lifetime breast cancer risk ranging from 41% to 90% and an ovarian cancer risk ranging from 20% to 48.3% [2], in addition to increased risks for other malignancies. For the unaffected carriers, the condition of living with a genetic mutation in the absence of disease has been conceptualized as previvorship. For the previvors the prevention strategies provide substantial risk reduction but involve options that carry a significant burden of both physical and psychological stress; moreover, individuals carrying hereditary breast/ovarian cancer–predisposing mutations may experience concerns about potentially transmitting the mutation to their children [3]. BRCA1/2 mutations are inherited in an autosomal dominant pattern, thus there is a 50% probability of transmitting the mutation to each child. This condition may affect the identity of mutation carriers [4], generate a “pervasive sense of responsibility toward others,” and engage individuals in potentially conflicting ethical decisions [5]. Women of reproductive age who test positive for a BRCA1/2 mutation may encounter difficulties in family planning and reproductive decision-making. The decision to have children evokes concerns related both to the probability of transmitting the mutation and to the possibility that parenting could be compromised by illness and/or premature death [6,7]. Thus, undergoing genetic testing has profound implications for individuals and families and may also affect future generations, a dimension conceptualized as “genetic legacy” [8]. Few studies have systematically examined the psychological condition of women carrying BRCA1/2 mutations in relation to the possibility of transmitting the mutation to their children and their reproductive decision-making processes. Existing literature indicates that the presence of multigenerational patterns of disease manifestation can shape developmental processes and contribute to psychological distress [9]. Distress in this population is primarily expressed through anxiety symptoms, whereas depressive symptoms are comparable to those of the general population [10]. Studies examining the impact of genetic testing on family relationships have shown that test results significantly influence relationships with partners, siblings, and children, fostering either greater cohesion or distancing depending on family dynamics [11]. Concerns about the risk of transmitting the mutation are widespread, and women carrying a genetic mutation may experience guilt toward their children and perceive themselves as responsible for placing their offspring at risk [4,12]. Feelings of guilt are more pronounced in patients with a previous cancer diagnosis and represent one of the most relevant emotional reactions following genetic testing. Guilt is associated with concerns about children's cancer risk but is not significantly influenced by age or by clinical risk management strategies [13]. It tends to remain stable over time, suggesting a link to the familial and relational dimensions of genetic risk rather than to personal disease risk perception [11]. Guilt may also challenge notions of parental equity, despite recognition of the random hereditary nature of genetic mutations [4]. Women carrying genetic mutations are less likely to desire children or may experience distress related to procreation. Reproductive decision-making is described as a complex and emotionally charged process in which genetic testing reshapes identity, future expectations, and moral responsibility [14]. Younger women often feel pressure to make rapid reproductive decisions, while women who already have children tend to balance hereditary risk with the positive experience of motherhood [14,15]. Approximately 40% of childless women report that genetic diagnosis influences decisions about biological parenthood, mainly due to fears of transmission and illness-related concerns [16]. The possibility of transmitting BRCA mutations is a key psychological factor in reproductive choices, with many women considering or adopting strategies to prevent genetic transmission [17]. Based on existing literature and clinical observations, the present study aims to explore the psychological functioning of BRCA1/2 mutation carriers, focusing on the role of guilt in emotional distress and its impact on reproductive decision-making. Materials and methods Sample A multicenter observational study was conducted. The study sample was recruited from the genetic counselling clinics of the Regina Elena National Cancer Institute in Rome, the University Hospital of Modena, the University of Insubria and ASST Sette Laghi in Varese, the Sant’Anna University Hospital and Local Health Trust in Ferrara, and Sant’Andrea Hospital in Rome between June 2022 and May 2025. A total of 110 participants were enrolled, including 53 previvors and 57 breast cancer patients. Elegibility criteria included: carriers of a pathogenic BRCA1/2 variant, with or without a diagnosis of breast cancer, who had at least one child; aged between 25 and 45 years at the time of BRCA1/2 mutation detection; minimum educational level of lower secondary school; availability and ability to complete questionnaires and interviews. Exclusion criteria were diagnosis of other oncological diseases; presence of cognitive impairment and/or inability to comply with study procedures. Measures Sociodemographic and clinical data were collected through a Sociodemographic and Clinical Data Form, including age at test completion, educational level, marital status, parental status, and employment condition. Clinical information included type of genetic mutation (BRCA1/BRCA2), breast cancer diagnosis (yes/no), and disease stage and treatments. Each patient took part into a semi-structured interview, adapted from Donnelly's semi-structured interview and the Psychological Aspects of Hereditary Cancer Genetic Testing Questionnaire (PAHC) [15]. The interview consists of two parts. The first part investigates four main dimensions: motivation for undergoing genetic testing (assessed through seven response options), reactions to a positive test result, perceived risk of transmitting the mutation to offspring, and emotional experience related to having transmitted or potentially transmitting the mutation (assessed using ad hoc items rated on a visual analogue scale 0–10). The second part examines the impact of BRCA1/2 mutation diagnosis on decisions to have or not have children (assessed through a visual analogue scale 0-10). Open-ended questions explored how women discovered the possibility of carrying a genetic mutation; how the diagnosis may have influenced reproductive decision-making; the motivations for deciding not to have children. Each patient was then asked to complete the following psychometric instruments. (i)The Interpersonal Guilt Rating Scale-15 (IGRS-15s) [18]. The IGRS-15s is a 15-item self-report questionnaire assessing three dimensions of guilt: survivor guilt, omnipotent responsibility guilt, and self-hate. Survivor guilt refers to the belief that success, or well-being may harm others. Omnipotent responsibility guilt refers to the pathogenic belief that one must make loved ones happy, perceiving one's own needs as selfish and hurtful. Self-hate is based on the pathogenic belief of being bad, inadequate, or worthless. Each item is rated on a five-point Likert scale ranging from 1 (not at all representative) to 5 (completely representative). The Interpersonal Guilt Rating Scale-15 (IGRS-15s) [18]. The IGRS-15s is a 15-item self-report questionnaire assessing three dimensions of guilt: survivor guilt, omnipotent responsibility guilt, and self-hate. Survivor guilt refers to the belief that success, or well-being may harm others. Omnipotent responsibility guilt refers to the pathogenic belief that one must make loved ones happy, perceiving one's own needs as selfish and hurtful. Self-hate is based on the pathogenic belief of being bad, inadequate, or worthless. Each item is rated on a five-point Likert scale ranging from 1 (not at all representative) to 5 (completely representative). (ii)The Patient Health Questionnaire-9 (PHQ-9) [19]. The PHQ-9 is a self-administered instrument used for assessing the severity of depression. Nine items assessing major depressive symptoms according to DSM-IV criteria, rated on a 4-point Likert scale from 0 (not at all) to 3 (nearly every day). Total scores range from 0 to 27. Depression severity is categorized as follows [20]: 5–9 = subthreshold depression; 10–14 = moderate depression; 15–19 = moderately severe depression; ≥20 = severe depression. A cut-off score of 10 indicates optimal sensitivity and specificity for identifying clinically relevant depression [21]. The Patient Health Questionnaire-9 (PHQ-9) [19]. The PHQ-9 is a self-administered instrument used for assessing the severity of depression. Nine items assessing major depressive symptoms according to DSM-IV criteria, rated on a 4-point Likert scale from 0 (not at all) to 3 (nearly every day). Total scores range from 0 to 27. Depression severity is categorized as follows [20]: 5–9 = subthreshold depression; 10–14 = moderate depression; 15–19 = moderately severe depression; ≥20 = severe depression. A cut-off score of 10 indicates optimal sensitivity and specificity for identifying clinically relevant depression [21]. Qualitative data were used to complement and deepen quantitative findings. Procedure The assessment of guilt, perceived risk of transmitting the genetic mutation, and depressive symptoms was conducted in the whole sample. Assessment of the impact of BRCA1/2 mutation diagnosis on reproductive decision-making was carried out exclusively in previvors. Eligible participants read and signed informed consent. The study was approved by the following ethics committees: Central Ethics Committee IRCCS Lazio – Experimental Registry No. 1702/22, meeting of 31/05/2022; Area Vasta Emilia Centro Committee – Registry No. 109/2023/Oss/AUSLFe, meeting of 15/02/2023; Insubria Ethics Committee (Study No. 197/2022), Minutes No. 114, meeting of 18/04/2023; Lazio Area 1 Territorial Ethics Committee, approval dated 30/08/2023, Note No. 0667/2023; Area Vasta Emilia Nord Ethics Committee, Prot. AOU 0007449/25, dated 12/03/2025. Data analysis We calculated descriptive statistics for all variables of interest. Continuous variables were reported as means and standard deviations (±SD), medians, and ranges (min–max), whereas categorical variables were described using absolute and percentage frequencies. The Kolmogorov–Smirnov normality test was applied to all continuous variables. To explore differences in continuous variables, we performed Student's t-tests or Mann–Whitney tests, according to variable distribution. Relationships between categorical variables were assessed using the Chi-square test. Correlations between variables were evaluated using Spearman's correlation coefficient. A p-value <0.05 was considered statistically significant. Univariate logistic regression models were used to identify variables that were associated with elevated scores in the Omnipotence, Survivor Guilt, Self-Hate and emotional reaction scores. We conducted a multivariate logistic regression model with the predictor variables that were significant in the univariate analyses. Statistical analyses were conducted using SPSS version 30.0 [22]. Results The sample consisted of 110 women carrying a BRCA1/2 genetic mutation. The mean age at the time of the study was 43 years (SD = 6.2), and the mean age at the time of genetic mutation diagnosis was 38 years (SD = 5). Among the participants, 53 were previvors and 57 had received a diagnosis of breast cancer. Most were married (n = 87, 79.1%). Educational level was 13 years for most patients (n = 47, 42.7%), but a high percentage were graduated (n = 41, 37.3%). Motivation for undergoing genetic testing Through the semi-structured interview, women were asked about their motivations for undergoing genetic testing, and they were allowed to select more than one reason. A total of 84.5% of the sample indicated the importance of being aware of their own condition; 79.1% reported the need to protect their children; 77.3% highlighted the importance of being informed in order to undertake preventive measures; 68.2% indicated the importance of information for evaluating the possibility of specific treatment; 64.5% stated that information was important for assessing the risk of developing other malignancies. Additionally, 48.2% reported the importance of protecting other family members (Table 1). Table 1Motivation for undergoing genetic testing (N = 110).Table 1MotivationN (%)To protect my children87 (79.1)To protect other family members53 (48.2)It is important for prevention85 (77.3)To be aware of my condition93 (84.5)To assess the possibility of specific treatment75 (68.2)To assess the risk of developing other malignancies71 (64.5)Other6 (5.5) Motivation for undergoing genetic testing (N = 110). Emotional distress and guilt assessment Emotional reaction to the test result Through the semi-structured interview, women were asked to rate their emotional reaction at the time the genetic mutation result was disclosed, assigning a score from 0 (not at all) to 10 (very much) to each of the following emotions: anger, sadness/discouragement, anxiety, worry, and guilt. The median scores for the entire sample were: 5 (range min-max 0–10) for anger; 7 (range min-max 0–10) for sadness/discouragement; 7 (range min-max 0–10) for anxiety; 8 (range min-max 0–10) for worry; and 1 (range min-max 0–10) for guilt (Table 2). Table 2Emotional reactions to genetic test results (N = 110).Table 2ItemNMedian (min–max)What did you feel when you received the test result? Anger1105 (0–10)What did you feel when you received the test result? Sadness/Distress1107 (0–10)What did you feel when you received the test result? Anxiety1107 (0–10)What did you feel when you received the test result? Worry1108 (0–10)What did you feel when you received the test result? Guilt1101 (0–10)Emotional Reaction to Having Transmitted the Mutation(among women whose children received a BRCA diagnosis) (N = 6)ItemNMedian (min-max)If your children received a BRCA diagnosis, what do you feel about having transmitted the mutation?Anger610 (9–10)Sadness/Distress610 (5–10)Anxiety610 (9–10)Worry610 (9–10)Guilt610 (6–10)Emotional Reaction to the Possibility of Transmitting the Mutation (N = 107)ItemNMedian (min–max)What do you feel about having transmitted or potentially transmitting your mutation?Anger1077 (0–10)Sadness/Distress1078 (0–10)Anxiety1079 (0–10)Worry10710 (0–10)Guilt1075 (0–10) Emotional reactions to genetic test results (N = 110). Correlation analyses conducted among emotional reactions showed that anger was significantly associated with sadness/discouragement (Spearman's Rho = 0.53, p < 0.001), anxiety (Rho = 0.28, p < 0.003), and worry (Rho = 0.25, p = 0.009). Sadness/discouragement was significantly correlated with anxiety (Rho = 0.53, p < 0.001) and worry (Rho = 0.58, p < 0.001). Anxiety was significantly associated with worry (Rho = 0.74, p < 0.001) and guilt (Rho = 0.32, p < 0.001). Guilt was significantly correlated with worry (Rho = 0.23, p = 0.016). All correlations were of modest to moderate strength except for the correlation between anxiety and worry, which was substantial. Emotional experience related to children All women in the sample had at least one child at the time of the study. All women—except those whose children had already undergone genetic testing—were asked to estimate the probability of transmitting the mutation to their children. The mean perceived probability was 5.62 (SD = 2.03). These same participants were asked to rate the emotional impact of the possibility of transmitting the mutation to their children, assigning a score from 0 (not at all) to 10 (very much) to each of the following emotions: anger, sadness/discouragement, anxiety, worry, and guilt. Median scores were: 7 (range 0–10) for anger; 8 (0–10) for sadness/discouragement; 9 (0–10) for anxiety; 10 (0–10) for worry; and 5 (0–10) for guilt (Table 2). A total of 7.3% of the women had children who had already undergone genetic testing. This corresponds to 5.38% of all children (10 out of 186); among them, 6 of the 10 tested children were found to carry the mutation. Women whose children tested positive for the mutation expressed median scores of 10 (range 9–10) for anger, worry, and anxiety; 10 (range 5–10) for sadness/discouragement; and 10 (range 6–10) for guilt (Table 2). Guilt assessment The IGRS questionnaire consists of three subscales: omnipotent responsibility guilt, self-hate, and survivor guilt. In our sample, the mean score on the omnipotent responsibility subscale was 2.84 (SD = 0.00), a value significantly higher (p = 0.002) than the normative mean score of 2.53 (SD = 0.65). The mean score on the survivor guilt subscale was 1.99 (SD = 1.09), and the mean score on the self-hate subscale was 1.21 (SD = 0.53). Both values are close to the normative data (survivor guilt: 2.28, SD = 0.83; self-hate: 1.64, SD = 0.77). A univariate logistic regression analysis was conducted to examine the association between emotional reaction to genetic test results and the three IGRS subscales. Results indicated that for each unit increase in emotional reaction to the test, there was a 4% increase in the odds of reporting an Omnipotence score above 2.53 (OR = 1.04; p = 0.030) and a 5% increase in the odds of reporting a Survivor Guilt score above 2.28 (OR = 1.05; p = 0.031) (Table 3). Table 3Univariate logisitc regression of emotional reaction to genetic test results and three IGRS subscales.Table 3Onnipotence (cut-off 2.53).Univariate logistic regressionOR (95%CI)p-valueEmotional reaction to test1.04 (1.00-1.08)0.030Survivor Guilt (cut-off 2.28).Univariate logistic regressionOR (95%CI)p-valueEmotional reaction to test1.05 (1.00-1.09)0.031Self Hate Guilt (cut-off 1.64).Univariate logistic regressionOR (95%CI)p-valueEmotional reaction to test1.02 (0.97-1.07)0.444 Univariate logisitc regression of emotional reaction to genetic test results and three IGRS subscales. Correlation analyses showed that emotional reaction to the possibility of transmitting the mutation to one's children was modestly and positively correlated with the Omnipotence subscale (Spearman's rho = 0.32; p < 0.001). Further correlation analyses revealed significant positive associations between depressed mood and all three IGRS subscales: Omnipotence (Spearman's rho = 0.21; p = 0.024), Survivor Guilt (Spearman's rho = 0.28; p = 0.003), and Self-Hate (Spearman's rho = 0.29; p = 0.003). Additionally, Survivor Guilt was significantly and positively correlated with the impact of genetic diagnosis on reproductive decision-making (Spearman's rho = 0.289; p = 0.044). Depressive mood At the PHQ-9, 22.7% (n = 25) showed a score ≥10, recognized as optimal for identifying clinically relevant depression [22]. Of these, most were moderately depressed (cut-off 10-14, n = 21, 19%) and only a few (n = 5, 4.5%) were moderately severe/severely depressed (score ≥15). The comparison between the Italian general population and our sample in terms of depression levels was statistically significant (Chi-square test, p < 0.001). Investigation of the reproductive decision-making process The investigation of reproductive decision-making was conducted exclusively in the sample of previvors. At the time of diagnosis, 92.4% of these women already had at least one child, and at the time of the study all women in the sample had at least one child. After receiving the diagnosis, 18.9% of the women had one child and 1.9% had two additional children. A total of 58.5% of the sample reported that the diagnosis of a genetic mutation had no impact on their decision to have children. The most frequently reported motivation among these women was that they had already had children at the time of diagnosis and did not desire additional children. Indeed, the relationship between number of children at diagnosis and the perceived impact of the diagnosis on reproductive decision-making showed a statistically significant inverse correlation (Spearman's Rho = −0.42, p = 0.002). A total of 11.4% of the population reported that the diagnosis had some impact on their decision to have children, indicating values between 2 and 5 on a 0–10 scale (Table 3). The most frequently reported motivation in this group was having accelerated the pregnancy timeline in order to proceed with preventive surgical interventions thereafter. Furthermore, 30.2% stated that the diagnosis had a strong impact on reproductive decision-making, indicating values between 6 and 10 (Table 3). The motivations reported by these women included the need to undergo preventive surgical procedures (15%) and fear of transmitting the mutation (4%). Additionally, 15.1% of the sample reported planning to have children in the future. There was a statistically significant inverse correlation between women's age and the decision to have children regardless of the genetic mutation diagnosis (Spearman's Rho = −0.46, p < 0.001). Comparison between the two groups: unaffected patients vs. breast cancer patients A comparison was conducted between the group of previvors and the group of patients diagnosed with breast cancer. A statistically significant difference emerged for age (Mann–Whitney test, p < 0.001) and for motivation to undergo genetic testing: oncological patients were significantly more likely (Pearson's Chi-square, p < 0.001) to indicate the need to assess the risk of developing additional malignancies as a motivation for testing. No significant differences were found in any of the other variables under investigation: emotional reactions to a positive genetic test result; emotional experiences related to children; guilt assessed through the IGRS; or depressive mood assessed through the PHQ-9. No significant differences were observed in the number of children between the two groups. Discussion Psychological distress related to the possibility of transmitting a genetic mutation to one's offspring has received limited attention in the literature. This study aimed to examine the psychological condition of women carrying a pathogenic variant, specifically exploring the presence of guilt, perceived risk of transmitting the mutation to their children, and the impact of diagnosis on reproductive decision-making. The motivations provided by participants for undergoing genetic testing highlight the importance of awareness and, consequently, control over one's condition. Individuals who undergo testing tended to actively manage their sense of self considering the information revealed by the results. Those who choose to undergo testing were typically active agents in making health-related decisions [4]. In our sample, 79.1% stated they underwent testing to protect their children. Thus, the need to safeguard one's children emerged very early in the diagnostic and therapeutic process and the motivation to pursue genetic testing appeared to stem from a desire to act in a morally responsible way and to limit cancer-related risks [15]. Following the communication of test results, participants reported high levels of psychological distress. Sadness/discouragement, worry, and anxiety were predominant, while anger and guilt were less pronounced. Emotional reactions were significantly correlated with each other, suggesting the presence of a broad and complex distress response. The anxiety levels observed in the sample align with previous findings: clinically significant anxiety has been documented in 31–44% of mutation carriers [10,23]. Anxiety symptoms may arise from the condition of being a mutation carrier, from personal experience of illness [24,25], from having multiple relatives with a history of breast/ovarian cancer [26], from being the first person in the family to be tested [27], and from the responsibility of communicating test results to relatives [28]. In our study, psychological distress was strongly linked to the possibility of transmitting the mutation to one's children. High levels of worry, sadness/discouragement, and anxiety were observed, but anger and guilt also reached noteworthy values. Women slightly overestimated the actual probability of transmission; this is consistent with literature showing that women from families with suspected hereditary cancer risk may rely on family history and cancer experiences as reference points for assessing risk and making decisions (Kenen et al., 2003). In Staton's study [3], 88% of participants frequently or extremely feared transmitting the mutation. Women whose children tested positive for the mutation showed extremely high levels of anger, worry, and anxiety, as well as substantial sadness/discouragement and guilt. These findings reinforce the idea, already supported in the literature [4], that the sense of identity in mutation carriers may be strongly shaped by relationships with significant others. Their sense of self appears to be closely intertwined with interpersonal relationships and the surrounding context. Emotional distress in this population was also confirmed by the high scores on guilt measures. Elevated omnipotent responsibility guilt indicated a tendency to assume excessive responsibility for the wellbeing or suffering of significant others, as well as difficulty differentiating actual and presumed responsibility [29]Survivor guilt and omnipotent responsibility guilt were linked to basic affective systems and were more intense among individuals who, during development, perceived their caregiver as distressed, in need of help, or troubled by separation and individuation processes [30]. This is coherent with the life histories of genetic mutation carriers [9]. Emotional reaction to genetic test results was predictive of specific dimensions of guilt. In particular, the associations observed for Omnipotence and Survivor Guilt suggest that a strong emotional response to testing may be associated with a greater tendency toward an over-responsibilizing representation of one's role. The correlation between emotional reaction to the possibility of transmitting the mutation to one's children and Omnipotence further indicates that the risk of transmission is not experienced solely as a medical risk, but also as a form of “potential guilt.” All dimensions of guilt (Omnipotence, Self-Hate, and Survivor Guilt) were significantly correlated with depressed mood. These findings suggest that guilt is not a unitary construct; rather, its different dimensions converge in contributing to depressive symptoms, likely through mechanisms such as over-responsibilization, self-devaluation, and negative social comparison. In our sample, 52.7% of participants showed some degree of depressive mood, and 20% had clinically relevant depression. Depressive symptoms were significantly higher than those observed in the general population. This contrasts with other findings where depression levels were comparable to normative values [10] and may be due to our inclusion criteria—specifically, the parental status of all participants. Guilt, as measured by the Survivor Guilt subscale, was associated with reproductive decision-making: women experiencing higher levels of survivor guilt reported a greater impact of genetic diagnosis on their decision to have children. From an interpretative perspective, this association may reflect difficulty in granting oneself the right to parenthood, which may be experienced as an additional “privilege” compared to others, as well as a tendency to subordinate personal desires to ethical or reparative considerations consistent with the core features of survivor guilt. At the time of the study, all women had one or more children, and most did not wish to have additional children. For those who already had children at the time of the test result, the impact of the diagnosis on reproductive decision-making was lower. This finding is consistent with that reported by Ref. [15], who observed that women who already have children tend to balance genetic risk with the positive experience of motherhood.” The diagnosis of a genetic mutation had a significant impact on reproductive decisions for 30.2% of the sample. For many of these women, the need to undergo prophylactic surgery (oophorectomy, hysterectomy) took precedence over childbearing; decisions not to have more children were based on personal cancer risk assessments. Among those reporting a strong impact of diagnosis on reproductive decisions, 4% stated they would not have additional children due to concerns about transmission. Literature reports higher percentages, with Chan and colleagues' study [16] showing that 17.2% stated they would not have children due to transmission risk, while Fortuny and colleagues [17], indicated that 12% would not conceive if a mutation were present. Fortuny et al. [14] reported that 48% of study participants would consider preimplantation genetic diagnosis (PGD) in the presence of a hereditary mutation. The availability of PGD may influence reproductive decision-making and potentially alleviate psychological distress associated with fear of transmitting the mutation and feelings of guilt. However, PGD remains a costly option, is not uniformly accessible across healthcare systems, and raises additional ethical concerns regarding genetic selection. Some women stated that the mutation diagnosis accelerated their reproductive plans prior to prophylactic surgery, appearing to respond to the ‘decisional urgency’ described by Hesse-Biber et colleagues [14], experiencing a compressed family life cycle by accelerating their pregnancy plans and attempting to manage their personal risk of HBOC [15]. Previous studies indicate that women often experience a “compressed family life cycle,” accelerating pregnancy plans to manage hereditary cancer risk [15,30,31]. Age was a crucial factor influencing the impact of diagnosis on reproductive decision-making: younger women perceived greater impact. This is consistent with literature showing that women under 35 are more likely to pursue parenthood after learning about their BRCA1/2 mutation and report a stronger influence of genetic status on romantic relationships [30]. A total of 20.8% of the sample had children after the diagnosis, and 15% reported plans for future childbearing despite the mutation. Indeed, despite concerns about transmitting the mutation, some carriers still desire natural conception [12,16]. Our findings are consistent with the proportions reported by Fortuny and colleagues [17], which showed that 36% of participants would have conceived children regardless of the genetic test results. Overall, these results suggest that a genetic mutation diagnosis does not have a uniform impact across all women carriers, but becomes particularly salient in specific subgroups, especially younger women and those who have not yet completed their reproductive plans.” No significant differences emerged between previvors and oncological patients, suggesting that the psychological impact of the mutation may be independent of disease status. Study limitations Despite its clinical relevance, the study has some limitations. First, emotional experiences related to having transmitted the mutation were analyzable in only 7.3% of the sample, limiting the generalizability of this specific finding. Moreover, the analysis of reproductive decision-making was conducted exclusively in women who already had at least one child, which may have attenuated the perceived impact of the mutation on reproductive choices. The decision to include only women who had at least one child was based on the primary objective of investigating maternal guilt associated with the potential transmission of BRCA1/2 mutations. However, consistent with previous literature [14], the present study confirms that the diagnosis of a hereditary mutation has a particularly significant impact among younger women and among those who have not yet completed their reproductive plans. These findings highlight the importance of further investigating reproductive decision-making in future studies by extending recruitment to women who have not yet had children. Conclusions The study provides a comprehensive picture of the psychological functioning of women who are carriers of genetic mutations. Participants reported elevated levels of emotional distress already at the time of disclosure of genetic test results, with a predominance of worry, anxiety, and sadness, which were further intensified when emotions were related to the possibility of transmitting the mutation to their children. Guilt emerged as a central and multidimensional construct. In particular, Omnipotence guilt was significantly higher than normative data. Moreover, all dimensions of guilt (i.e., Omnipotence, Self-Hate, and Survivor Guilt) were significantly associated with depressed mood, suggesting that guilt may represent a relevant psychological vulnerability factor in this population. Levels of depressed mood were also significantly higher than those observed in the general population. Perceived risk of transmission is slightly higher than actual risk. The diagnosis of a genetic mutation has a significant impact on reproductive decision-making for 30.2% of the sample, mainly due to the need to prioritize prophylactic surgery. The study highlights the importance of providing appropriate psychological support to women carrying a genetic mutation throughout psycho-oncological care and psychotherapy. With regard to decision-making support and the management of communication within the family, genetic counselling remains the most widely adopted intervention. Several studies have demonstrated the effectiveness of Cognitive Behavioral Therapy (CBT) in the treatment of depression among cancer patients, with benefits observed both in the short term and at follow-up assessments [32,33]. These findings suggest that CBT may also be valuable in the hereditary cancer setting, not only for the treatment of depressive symptoms but also for addressing dysfunctional cognitive schemas related to guilt and self-devaluation. Among acceptance-based interventions, Acceptance and Commitment Therapy (ACT) appears particularly well suited to the hereditary cancer context, as it focuses on enhancing individuals’ ability to tolerate uncertainty and to engage in value-consistent behaviors despite the presence of fear and distress [34]. Data availability statement The data that support the findings of this study are openly available at: https://gbox.garr.it/garrbox/s/dEqa85nyaKV3Zrl. Funding sources This work was financially supported through funding from the institutional “Ricerca Corrente” granted by the Italian Ministry of Health. CRediT authorship contribution statement Anita Caruso: Conceptualization, Funding acquisition, Investigation, Methodology, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. Luigi Grassi: Conceptualization, Methodology, Validation, Visualization, Writing – original draft. Anna Costantini: Conceptualization, Methodology, Writing – review & editing. Eugenia Trotti: Investigation, Writing – review & editing. Rosangela Caruso: Investigation, Writing – review & editing. Chiara Maria Navarra: Investigation. Marco Luigi Bellani: Investigation. Ileana Carnevali: Investigation. Elena Barbieri: Investigation. Marco Cruciata: Investigation. Marco Canfora: Data curation, Resources, Software. Francesca Sperati: Formal analysis, Resources. Antonella Savarese: Investigation. Elisabetta Razzaboni: Conceptualization, Methodology, Writing – review & editing. Lara Guariglia: Conceptualization, Funding acquisition, Investigation, Methodology, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. Declaration of competing interest The corresponding author declares on behalf of all authors that there are no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgments The authors are indebted to Federica Falcioni, Administrative Assistant, Scientific Direction, IRE. Footnotes RC and LG have been supported by #NEXTGENERATIONEU (NGEU) (Ministry of Health, National Recovery and Resilience Plan (NRRP) project PNRR-MAD-2022-12375899 Cost-effectiveness of innovative, non-pharmacological strategies for early detection, prevention and tailored care of depressive disorders among cancer patients: Transcranial Magnetic Stimulation and Virtual Reality based Cognitive Remediation. References Associated Data Data Availability Statement The data that support the findings of this study are openly available at: https://gbox.garr.it/garrbox/s/dEqa85nyaKV3Zrl.